Silicon Therapeutics Announces Dosing of First Patient in Phase 1 Open-Label Clinical Trial of SNX281 for Advanced Solid Tumors or Lymphoma

BOSTON--(BUSINESS WIRE)-- #AI--Silicon Therapeutics announces treatment of first patient with its therapeutic candidate SNX281 in a Phase 1 clinical trial.